Interpretation of the 2016 European Thyroid Association/European Group on Graves′ Orbitopathy Guidelines for the management of Graves′ orbitopathy

In March 2016, European Thyroid Association/European Group on Graves′ Orbitopathy(EUGOGO)published a guideline for the management of Graves′ orbitopathy(GO). Compared with the consensus statement of EUGOGO on management of GO, the guideline presents the selenium supplementation for mild GO, the first-line and second-line therapy for moderate-to-severe and active GO and the surgery for moderate-to-severe and inactive GO in detail, which adopts grading of recommendations and level of evidence and incorporates the results of recent clinical randomized trials. The guideline includes 17 specific recommendations. The treatment of patients with severe GO, and those who do not response to glucocoticoids is still a challenge. The novel agents will have to be awaited with the results of clinical studies. (Chin J Endocrinol Metab, 2016, 32: 886-888) Key words: Graves′ orbitopathy; Selenium; Glucocorticoids; Rituximab